Compare Lemonade Inc (LMND) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Sana Biotechnology Inc — how do they compare? Lemonade Inc trades at $51.66 (market cap $4.09B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Lemonade Inc is far larger — about 3.6× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| LMND | SANA | |
|---|---|---|
Market Cap | $4.09B | $1.13B |
Sector | Financials | Health |
52-Week High | $96.57 | $5.92 |
52-Week Low | $47.38 | $2.68 |
Enterprise Value | $3.95B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $51.63, down 1.99% on the day, with a bearish technical signal from moving averages. Revenue growth is strong, reaching $737.9M in 2025, but the company remains unprofitable with a net income margin of -14.19%. Recent Q2 2026 earnings beat expectations, and the company targets positive adjusted EBITDA by Q4 2026, yet the stock faces selling pressure amid valuation concerns.
The outlook hinges on Lemonade's path to profitability; achieving its EBITDA target could drive upside toward the $58 consensus price target. Key risks include persistent losses, competitive pressures, and execution challenges in scaling its AI-driven insurance model. Investor sentiment is divided, reflecting the high-growth but high-burn profile.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
